Vol. 6 No. 4 (2026): April
Reimbursement Reviews

Lemborexant (Dayvigo)

decorative image of the issue cover

Published April 16, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses lemborexant (Dayvigo), 5 mg film-coated tablet and 10 mg film-coated tablet, oral.
  • Indication: The treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.